October 17, 2016
Mylan was hit with a proposed class action in California federal court on Monday alleging that EpiPen price hikes in excess of 500 percent over the last decade have ripped off purchasers in need of a lifesaving product, following the company's $465 million deal with federal prosecutors over the drug.